Search Results - "KOSOGLOU, Teddy"

JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans by Fourie, Anne M., Cheng, Xiaoli, Chang, Leon, Greving, Carrie, Li, Xinyi, Knight, Beverly, Polidori, David, Patrick, Aaron, Bains, Trpta, Steele, Ruth, Allen, Samantha J., Patch, Raymond J., Sun, Chengzao, Somani, Sandeep, Bhandari, Ashok, Liu, David, Huie, Keith, Li, Shu, Rodriguez, Michael A., Xue, Xiaohua, Kannan, Arun, Kosoglou, Teddy, Sherlock, Jonathan P., Towne, Jennifer, Holland, M. Claire, Modi, Nishit B.

“…The interleukin (IL)-23 pathway is a pathogenic driver in psoriasis, psoriatic arthritis, and inflammatory bowel disease. Currently, no oral therapeutics…”
Get full text

Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects by Kosoglou, Teddy, Reyderman, Larisa, Tiessen, Renger G., van Vliet, André A., Fales, Robert R., Keller, Robert, Yang, Bo, Cutler, David L.

“…Purpose The aim of our study was to evaluate the pharmacology of vorapaxar (SCH 530348), an oral PAR-1 antagonist, in healthy volunteers. Methods and results…”
Get full text

Hypothalamic-Pituitary-Adrenal Axis Effects of Mometasone Furoate/Formoterol Fumarate vs Fluticasone Propionate/Salmeterol Administered Through Metered-Dose Inhaler by Kosoglou, Teddy, PharmD, Hubbell, James, PhD, Cutler, David L., MD, Johnson-Levonas, Amy O., PhD, Xu, Danlin, PhD, Kantesaria, Bhavna S., MS, Kim, Kenneth, MD, Miller, S. David, MD

“…Background The effects of mometasone furoate and fluticasone propionate on the hypothalamic-pituitary-adrenal axis were compared when administered from…”
Get full text

Disposition of the Selective Cholesterol Absorption Inhibitor Ezetimibe in Healthy Male Subjects by PATRICK, James E, KOSOGLOU, Teddy, CAYEN, Mitchell N, STAUBER, Kathe L, ALTON, Kevin B, MAXWELL, Stephen E, YALI ZHU, STATKEVICH, Paul, IANNUCCI, Robert, CHOWDHURY, Swapan, AFFRIME, Melton

“…Ezetimibe [SCH 58235; 1-(4-fluorophenyl)-3( R )-[3-(4-fluorophenyl)-3( S )-hydroxypropyl]-4( S )-(4-hydroxyphenyl)-2-azetidinone], a selective cholesterol…”
Get full text

HPA Axis Effects of Mometasone Furoate/Formoterol (MF/F) Versus Fluticasone Propionate/Salmeterol (FP/S) Administered via Metered-Dose Inhaler (MDI by Kosoglou, Teddy, PharmD, Hubbell, James, PhD, Xuan, Fengjuan, PhD, Cutler, David, MD, Johnson-Levonas, Amy, PhD, Xu, Danlin, PhD, Kantesaria, Bhavna, MS, Kim, Kenneth, MD, Miller, S. David, MD

Get full text

Once-daily evening dosing of mometasone furoate administered via a dry powder inhaler does not adversely affect the hypothalamic-pituitary-adrenal axis by Kosoglou, Teddy, Cutler, David L, Staudinger, Heribert, Herron, Jerry M

“…Inhaled corticosteroids can suppress the hypothalamic-pituitary-adrenal (HPA) axis with long-term exposure. This study reports the effects of moderate-dose…”
Get more information

Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses by Affrime, M B, Kosoglou, T, Thonoor, C M, Flannery, B E, Herron, J M

“…To investigate the potential for mometasone furoate (MF) to exert systemic effects following administration by dry powder inhaler (DPI) or metered-dose inhaler…”
Get more information

Effects of Ezetimibe on Cyclosporine Pharmacokinetics in Healthy Subjects by Bergman, Arthur J., Burke, Joanne, Larson, Patrick, Johnson-Levonas, Amy O., Reyderman, Larisa, Statkevich, Paul, Kosoglou, Teddy, Greenberg, Howard E., Kraft, Walter K., Frick, Glenn, Murphy, Gail, Gottesdiener, Keith, Paolini, John F.

“…This single‐center, open‐label, 2‐period crossover study investigated the effects of multiple‐dose ezetimibe (EZE) on a single dose of cyclosporine (CyA)…”
Get full text

Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial by Finberg, Robert W, Lanno, Riin, Anderson, David, Fleischhackl, Roman, van Duijnhoven, Wilbert, Kauffman, Robert S, Kosoglou, Teddy, Vingerhoets, Johan, Leopold, Lorant

“…Pimodivir, a first-in-class inhibitor of influenza virus polymerase basic protein 2, is being developed for hospitalized and high-risk patients with influenza…”
Get full text

A Phase 2 Study of Pimodivir (JNJ-63623872) in Combination With Oseltamivir in Elderly and Nonelderly Adults Hospitalized With Influenza A Infection: OPAL Study by O’Neil, Brian, Ison, Michael G, Hallouin-Bernard, Marie Charlotte, Nilsson, Anna C, Torres, Antoni, Wilburn, John M, van Duijnhoven, Wilbert, Van Dromme, Ilse, Anderson, David, Deleu, Sofie, Kosoglou, Teddy, Vingerhoets, Johan, Rossenu, Stefaan, Leopold, Lorant

“…Abstract Background Both the elderly and individuals with comorbidities are at increased risk of developing influenza-related complications. Novel influenza…”
Get full text

Mometasone furoate nasal spray : A review of safety and systemic effects by ZITT, Myron, KOSOGLOU, Teddy, HUBBELL, James

“…The development of corticosteroids that are delivered directly to the nasal mucosa has alleviated much of the concern about the systemic adverse effects…”
Get full text

Neutral endopeptidase inhibition: augmented atrial and brain natriuretic peptide, haemodynamic and natriuretic responses in ovine heart failure by Rademaker, M T, Charles, C J, Espiner, E A, Nicholls, M G, Richards, A M, Kosoglou, T

“…1. Atrial and brain natriuretic peptide are both circulating hormones subject to degradation by neutral endopeptidase 24.11. Whereas endogenous levels of…”
Get more information

Ezetimibe : A review of its metabolism, pharmacokinetics and drug interactions by KOSOGLOU, Teddy, STATKEVICH, Paul, JOHNSON-LEVONAS, Amy O, PAOLINI, John F, BERGMAN, Arthur J, ALTON, Kevin B

“…Ezetimibe is the first lipid-lowering drug that inhibits intestinal uptake of dietary and biliary cholesterol without affecting the absorption of fat-soluble…”
Get full text

Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment by Statkevich, Paul, Kosoglou, Teddy, Preston, Richard A., Kumar, Bharath, Xuan, Fengjuan, Trusley, Craig, Schiller, James E., Langdon, Ronald B., Cutler, David L.

“…Purpose To determine whether hepatic impairment has an effect on the pharmacokinetics (PK) of vorapaxar or M20, its main pharmacologically active metabolite…”
Get full text

The Effect of Multiple Doses of Ketoconazole or Rifampin on the Single- and Multiple-Dose Pharmacokinetics of Vorapaxar by Kosoglou, Teddy, Statkevich, Paul, Kumar, Bharath, Xuan, Fengjuan, Schiller, James E., Johnson-Levonas, Amy O., Young, Sophia, Cutler, David L.

“…This randomized, open‐label, parallel‐group study evaluated the effects of multiple‐dose ketoconazole or rifampin on the single‐ and multiple‐dose…”
Get full text

Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease by Kosoglou, Teddy, Kraft, Walter K., Kumar, Bharath, Statkevich, Paul, Xuan, Fengjuan, Ma, Lei, Jennings, Lisa K., Schiller, James E., Langdon, Ronald B., Cutler, David L.

“…Purpose To determine whether impaired renal function alters the pharmacokinetics (PK) of vorapaxar or its ability to inhibit thrombin receptor agonist peptide…”
Get full text

No Pharmacokinetic Drug–Drug Interaction Between Prasugrel and Vorapaxar Following Multiple‐Dose Administration in Healthy Volunteers by Anderson, Matt S., Kosoglou, Teddy, Statkevich, Paul, Li, Jing, Rotonda, Jennifer, Meehan, Alan G., Cutler, David L.

“…Vorapaxar is a first‐in‐class antagonist of the protease‐activated receptor‐1, the primary thrombin receptor on human platelets, which mediates the downstream…”
Get full text

Pharmacokinetics of vorapaxar and its metabolite following oral administration in healthy Chinese and American subjects by Chen, Xia, Kosoglou, Teddy, Statkevich, Paul, Kumar, Bharath, Li, Jing, Dockendorf, Marissa F, Wang, Guoqin, Lowe, Robert S, Jiang, Ji, Liu, Hongzhong, Wang, Zaiqi, Cutler, David L, Hu, Pei

“…Vorapaxar is a proteaseactivated receptor (PAR)-1 antagonist being developed for the prevention and treatment of thrombotic vascular events. To evaluate…”
Get full text

Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin by Kosoglou, Teddy, Zhu, Yali, Xuan, Fengjuan, Black, Laura, Johnson-Levonas, Amy O., Martinho, Monika, Statkevich, Paul, Cutler, David L.

“…Purpose Vorapaxar is an orally active protease-activated receptor 1 (PAR-1) antagonist that inhibits thrombin-induced platelet aggregation. This open-label…”
Get full text

No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects by Kosoglou, Teddy, Reyderman, Larisa, Kasserra, Claudia, Jennings, Lisa K., Young, Sophia, Xuan, Fengjuan, Pei, Jinglan, Maxwell, Stephen E., Schiller, James, Meehan, Alan G., Cutler, David L.

“…Background Vorapaxar, a novel antiplatelet agent in advanced clinical development for the prevention and treatment of atherothrombotic disease, is a potent,…”
Get full text